Study of HER2‐mutant lung cancers reveals at least 31 different HER2 variants with different sensitivities to afatinib (the predominant variant, A775_G776insYVMA, is resistant); Co‐mutations in TP53 and the PI3K pathway confer additional resistance: #LCSM